Meeting Banner
Abstract #0718

Hyperpolarized [1-13C]Pyruvate MRSI at 48 hrs post anti-VEGF Treatment Predicts Response in C6 Glioma Implanted Rats

Keshav Datta1,2, Mette Hauge Lauritzen1, Milton Merchant3, Taichang Yang3, Shie-Chau Liu1, Ronald Watkins1, Ralph Hurd1, Lawrence Recht3, and Daniel Mark Spielman1,2

1Radiology, Stanford University, Stanford, CA, United States, 2Electrical Engineering, Stanford University, Stanford, CA, United States, 3Neurology, Stanford University, Stanford, CA, United States

Using a bolus injection of hyperpolarized [1-13C]Pyruvate, we show that measurement of the resulting 13C-Lactate to 13C-Bicarbonate ratio 48-hours post-treatment with anti-angiogenic drug Bevacizumab (Bev20) predicts survival in a C6-Glioma rat model. A positive correlation of Lac/Bic with tumor growth rate further supports our hypothesis that the effect of the drug in survivors is to reverse the tumor Warburg metabolic phenotype necessary to support rapid proliferation.

This abstract and the presentation materials are available to members only; a login is required.

Join Here